BRCA1 5272-1G>A and BRCA2 5374delTATG are founder mutations of high relevance for genetic counselling in breast/ovarian cancer families of Spanish origin

被引:11
作者
Infante, M. [1 ]
Duran, M. [1 ]
Acedo, A. [1 ]
Perez-Cabornero, L. [1 ]
Sanz, D. J. [1 ]
Garcia-Gonzalez, M. [2 ]
Beristain, E. [3 ]
Esteban-Cardenosa, E. [4 ]
de la Hoya, M. [5 ,6 ]
Teule, A.
Vega, A. [7 ]
Tejada, M-I [3 ]
Lastra, E. [2 ]
Miner, C. [1 ]
Velasco, E. A. [1 ]
机构
[1] UVa CSIC, Grp Genet Canc, Inst Biol & Genet Mol, Valladolid 47003, Spain
[2] Hosp Gen Yague, Serv Oncol, Burgos, Spain
[3] Hosp Cruces, Genet Mol Lab, Dept Bioquim, Baracaldo, Spain
[4] Hosp Univ La Fe, Mol Biol Lab, Serv Biopatol Clin, Valencia, Spain
[5] Hosp Clin San Carlos, Oncol Mol Lab, Madrid, Spain
[6] Inst Salud Carlos III, Spanish Minist Sci & Innovat, Madrid, Spain
[7] CIBERER, FPGMX, SERGAS, Santiago De Compostela, Spain
关键词
BRCA1; BRCA2; breast cancer; founder mutations; ovarian cancer; BREAST-CANCER; HIGH PROPORTION; HETERODUPLEX ANALYSIS; PHENOTYPE ANALYSIS; HAPLOTYPE; POPULATION; IDENTIFICATION; FREQUENCY; RISKS; SPAIN;
D O I
10.1111/j.1399-0004.2009.01272.x
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
The distribution of BRCA1 and BRCA2 germ line mutations in breast/ovarian cancer families varies among different populations, which typically present a wide spectrum of unique mutations. Splicing mutation 5272-1G > A of BRCA1 and frameshift mutation 5374delTATG of BRCA2 are highly prevalent mutations in Castilla-Leon (Spain), accounting for 18.4% and 13.6% of BRCA1 and BRCA2 positive families, respectively. To test the presence of founder effects, 9 Spanish 5272-1G > A and 13 5374delTATG families were genotyped with polymorphic markers linked to BRCA1 or BRCA2. All the 5272-1G > A families shared a common haplotype in eight markers (1.1 Mb region) and the mutation age was estimated in 15 generations (similar to 380 years). A conserved haplotype associated to 5374delTATG was observed in four markers (0.82 Mb). The mutation occurred approximately 48 generations ago (similar to 1200 years). Each mutation likely arose from a common ancestor that could be traced to a small area of Castilla-Leon and expanded to other Spanish regions. They can have a significant impact on the clinical management of asymptomatic carriers as well as on the genetic screening strategy to be followed in populations with Spanish ancestries.
引用
收藏
页码:60 / 69
页数:10
相关论文
共 50 条
  • [1] BRCA1 and BRCA2 germline mutations screening in Algerian breast/ovarian cancer families
    Cherbal, Farid
    Bakour, Rabah
    Adane, Saida
    Boualga, Kada
    Benais-Pont, Gaelle
    Maillet, Philippe
    DISEASE MARKERS, 2010, 28 (06) : 377 - 384
  • [2] Germline Mutations of BRCA1 and BRCA2 in Korean Breast and/or Ovarian Cancer Families
    Kang, Hio Chung
    Kim, Il-Jin
    Park, Jae-Hyun
    Kwon, Hyuk-Jun
    Won, Yong-Jin
    Heo, Seung Chul
    Lee, Sang-Yon
    Kim, Kyung-Hee
    Shin, Yong
    Noh, Dong Young
    Yang, Dae-Hyun
    Choe, Kuk Jin
    Lee, Bong Hwa
    Kang, Soon Beom
    Park, Jae-Gahb
    HUMAN MUTATION, 2002, 20 (03) : 235
  • [3] BRCA1 and BRCA2 founder mutations account for 78% of germline carriers among hereditary breast cancer families in Chile
    Alvarez, Carolina
    Tapia, Teresa
    Perez-Moreno, Elisa
    Gajardo-Meneses, Patricia
    Ruiz, Catalina
    Rios, Mabel
    Missarelli, Claudio
    Silva, Mariela
    Cruz, Adolfo
    Matamala, Luis
    Carvajal-Carmona, Luis
    Camus, Mauricio
    Carvallo, Pilar
    ONCOTARGET, 2017, 8 (43) : 74233 - 74243
  • [4] Screening for BRCA1 and BRCA2 mutations in eastern Finnish breast/ovarian cancer families
    Hartikainen, J. M.
    Kataja, V.
    Pirskanen, M.
    Arffman, A.
    Ristonmaa, U.
    Vahteristo, P.
    Ryynanen, M.
    Heinonen, S.
    Kosma, V-M
    Mannermaa, A.
    CLINICAL GENETICS, 2007, 72 (04) : 311 - 320
  • [5] Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2
    M J L Ligtenberg
    F B L Hogervorst
    H W Willems
    P J W Arts
    G Brink
    S Hageman
    E A J Bosgoed
    E Van der Looij
    M A Rookus
    P Devilee
    E M A W Vos
    G Wigbout
    P M Struycken
    F H Menko
    E J Th Rutgers
    E H Hoefsloot
    E C M Mariman
    H G Brunner
    L J Van’t Veer
    British Journal of Cancer, 1999, 79 : 1475 - 1478
  • [6] Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2
    Ligtenberg, MJL
    Hogervorst, FBL
    Willems, HW
    Arts, PJW
    Brink, G
    Hageman, S
    Bosgoed, EAJ
    Van der Looij, E
    Rookus, MA
    Devilee, P
    Vos, EMAW
    Wigbout, G
    Struycken, PM
    Menko, FH
    Rutgers, EJT
    Hoefsloot, EH
    Mariman, ECM
    Brunner, HG
    Van't Veer, LJ
    BRITISH JOURNAL OF CANCER, 1999, 79 (9-10) : 1475 - 1478
  • [7] Three novel BRCA1/BRCA2 mutations in breast/ovarian cancer families in Croatia
    Levanat, Sonja
    Musani, Vesna
    Cvok, Mirela Levacic
    Susac, Ilona
    Sabol, Maja
    Ozretic, Petar
    Car, Diana
    Eljuga, Domagoj
    Eljuga, Ljerka
    Eljuga, Damir
    GENE, 2012, 498 (02) : 169 - 176
  • [8] The contribution of founder mutations in BRCA1 to breast and ovarian cancer in Lithuania
    Elsakov, P.
    Kurtinaitis, J.
    Petraitis, S.
    Ostapenko, V.
    Razumas, M.
    Razumas, T.
    Meskauskas, R.
    Petrulis, K.
    Luksite, A.
    Lubinski, J.
    Gorski, B.
    Narod, S. A.
    Gronwald, J.
    CLINICAL GENETICS, 2010, 78 (04) : 373 - 376
  • [9] BRCA1 and BRCA2 Genetic Testing in Breast and/or Ovarian Cancer Families in Iran
    Keshavarzi, Fatemeh
    Javadi, Gholam Reza
    Nafissi, Nahid
    Akbari, Mohammad Esmail
    Yassaee, Vahid Reza
    Farzad, Maryam Sharafi
    Zeinali, Sirous
    YAKHTEH, 2010, 12 (03): : 329 - 340
  • [10] A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families
    P Vahteristo
    H Eerola
    A Tamminen
    C Blomqvist
    H Nevanlinna
    British Journal of Cancer, 2001, 84 : 704 - 708